NCT00480935终止2 期
A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- To assess the radiologic response rate associated with 1 cycle of Sutent for neoadjuvant treatment of patients with renal cell carcinoma
研究概览
简要总结
Study Hypothesis: Patients with local renal cell carcinoma who are treated neoadjuvantly with Sutent may show a radiologic response to the study drug (Sutent).
The study is looking at the neoadjuvant (pre-surgery) administration of Sutent in patients with localized kidney cancer. The purpose of this research is also to evaluate both the safety and effectiveness of Sutent in this patient population.
详细描述
Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week rest period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period. After surgery, patients will have follow-up visits at 6 weeks and 3 months. Patients will be followed for 3 years after completions to assess late toxicities, time to progression and progression-free survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed renal cell carcinoma with a component of clear (conventional) cell histology, which has been assessed with biopsy at screening.
- •Locally confined tumour ≤ 7 cm
- •Has not undergone nephrectomy and is a candidate for surgical treatment of renal cell carcinoma
- •Male or female, 18 years of age or older
- •ECOG performance status 0 or 1
- •Adequate organ function as defined by the following criteria:
- •Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2.5 x central laboratory upper limit of normal (CL-ULN), or AST and ALT less than or equal to 5 x CL ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin less than or equal to 1.5 x CL-ULN
- •Absolute neutrophil count (ANC) greater than or equal to 1500/mL
- •Platelets greater than or equal to 100,000/mL
- •Hemoglobin greater than or equal to 9.0 g/dL
- •Serum calcium less than or equal to 12.0 mg/dL
- •Serum creatinine less than or equal to 1.5 x CL-ULN
- •Prothrombin time (PT) less than or equal to 1.5 x CL-ULN
- •Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
排除标准
- •Prior therapy of any kind for RCC (including nephrectomy, immunotherapy, chemotherapy, radiation, hormonal, or investigational therapy)
- •Abnormal ECG- including long QT/QTc interval, AV block or arrythmia
- •Tumour associated with local extension into adjacent tissues
- •Tumour associated with renal/vena caval thrombus
- •Tumour associated with lymphadenopathy (lymph node > 1 cm)
- •Evidence of rapidly progressive disease or other factors requiring surgery to take place before the 12 weeks scheduled for neoadjuvant treatment
- •Major surgery within 4 weeks of commencing study treatment
- •Any toxicity with a NCI CTCAE grade 3 or 4
- •Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer
- •Evidence of metastatic renal cell carcinoma
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
- •Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
- •Current treatment on another clinical trial
- •Pregnancy or breastfeeding
研究组 & 干预措施
Sunitinib Malate (Sutent)
Experimental
Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
干预措施: Sunitinib Malate (Sutent) (Drug)
结局指标
主要结局
To assess the radiologic response rate associated with 1 cycle of Sutent for neoadjuvant treatment of patients with renal cell carcinoma
时间窗: 5 weeks
次要结局
- To evaluate the safety and tolerability of Sutent given preoperatively(5 weeks)
- To assess the change in tumour vascularity in response to 1 cycle of neoadjuvant treatment of patients with renal cell carcinoma(5 weeks)
- To assess the change in expression of the following tissue markers; PDGF-alpha, PDGF-Beta, Flt-3, VEGFR and c-KIT, as compared to pre-treatment biopsy tissue as well as to stage, gender and age-matched controls(5 weeks)
- To assess late toxicities, time to progression, progression free survival, and survival(5 weeks - 3 years)
- A DNA microarray will be used for gene expression profiling of the tissue harvested at biopsy and surgery to investigate differential expression profiles and their association with Sutent sensitivity or resistance(5 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerRenal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT04958473Tianjin Medical University Second Hospital40
Unknown
2 期
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsMetastatic Renal Cell CarcinomaNCT02330783Peking University Cancer Hospital & Institute106
已完成
2 期
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabMetastatic Renal Cell CarcinomaNCT03126331Case Comprehensive Cancer Center26
Unknown
不适用
Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant TherapyRectal CancerSurgeryNCT03548844Yanhong Deng326
招募中
不适用
Randomized phase II study of neoadjuvant chemoradiotherapy (S-1+radiation) for resectable pancreatic cancer with less than 180 degree portal vein abutmentresectable pancreatic cancer with less than 180 degree portal vein abutmentJPRN-UMIN000027633agoya University, Graduate School of Medicine56